France-headquartered Solabia Group, a specialist in biotech-derived actives for the health and beauty sectors, has agreed to acquire Mibelle Biochemistry.
A Swiss company of international standing, Mibelle Biochemistry is widely recognized for its expertise in developing and producing high-performance active ingredients for the cosmetics, nutraceutical, and food industries. It is currently owned by Persán, a Spain-based multinational group and European leader in home and personal care products, following its acquisition of the full Mibelle Group last year.
Founded in 1991, Mibelle Biochemistry offers a portfolio of science‑backed products spanning skin care, healthy aging, hair care, and cognitive support. Its ingredients are distributed in more than 50 countries, and the company is recognized globally for its ability to transform nature’s concepts into effective, innovative ingredients.
Through this acquisition of Solabia intends to strengthen its positions in natural active ingredients, thanks to the union of the two organizations’ complementary expertise in biotechnology and plant-based science. “Customers will benefit from a broader portfolio while continuing to rely on the renowned Swiss‑made quality of Mibelle Biochemistry,” the company said in a press release.
“We are very excited to welcome Mibelle Biochemistry’s expert teams to Solabia. Mibelle Biochemistry is a company we have long admired for its scientific rigor, innovative spirit, and pioneering work. Together, we will accelerate innovation, expand our global reach, and deliver even stronger value to a larger customer base seeking differentiated, science‑backed solutions for beauty and wellbeing,” said Jean‑Baptiste Dellon, Chief Executive Officer of Solabia.
“Over more than three decades, Mibelle Biochemistry has built a global reputation for cutting‑edge biotechnology and high‑quality natural active ingredients. Joining Solabia marks an exciting next chapter for our team. We are gaining a strong, highly aligned partner who understands our markets and shares our passion for scientific excellence. This transaction will allow us to innovate faster, scale our technologies, and bring even more impactful ingredients to customers around the world,” commented Cornelia Schürch, Head of Mibelle Biochemistry.
In November, Mibelle Biochemistry introduced a next-generation senolytic active ingredient, SenoCellTec. Developed to address the root causes of skin aging, this innovative complex combines three plant extracts to selectively eliminate senescent (“zombie”) cells. At the same time, it helps stimulate skin stem cells and restore dermal thickness through a unique “cleanse–fill–revitalize” mechanism —supporting visibly rejuvenated, more resilient skin.
The transaction is expected to close in the coming months. Financial terms were not disclosed.
